paliperidone palmitate

FDA Drug Profile — Erzofri extended-release, INVEGA TRINZA, INVEGA SUSTENNA, INVEGA HAFYERA

paliperidone palmitate is listed in the FDA National Drug Code directory with 17 NDC codes, marketed under brand names including Erzofri extended-release, INVEGA TRINZA, INVEGA SUSTENNA. Available dosage forms: injection, injection, suspension, extended release.

Drug Details

Generic Name
paliperidone palmitate
Brand Names
Erzofri extended-release, INVEGA TRINZA, INVEGA SUSTENNA, INVEGA HAFYERA
Application Number
NDA216352
Sponsor
Shandong Luye Pharmaceutical Co., Ltd.
NDC Codes
17
Dosage Forms
INJECTION, INJECTION, SUSPENSION, EXTENDED RELEASE
Routes
INTRAMUSCULAR
Active Ingredients
PALIPERIDONE PALMITATE

Indications and Usage

1 INDICATIONS AND USAGE INVEGA SUSTENNA (paliperidone palmitate) is indicated for the treatment of: Schizophrenia in adults [see Clinical Studies (14.1) ]. Schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants [see Clinical Studies (14.2) ]. INVEGA SUSTENNA is an atypical antipsychotic indicated for Treatment of schizophrenia in adults. ( 1 ) Treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants. ( 1 )